Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hims & Hers Health ( (HIMS) ) has shared an announcement.
On March 9, 2026, Hims & Hers announced a strategic overhaul of its U.S. weight-loss business, aligning it with its global model by prioritizing a wider range of FDA-approved GLP-1 medications and limiting the use of compounded semaglutide to select clinical cases. As part of this shift, the company entered a collaboration with Novo Nordisk to add Ozempic and Wegovy products to its platform, stopped advertising compounded GLP-1s, and secured dismissal without prejudice of Novo Nordisk’s lawsuit, reinforcing its positioning as a scaled, consumer health distribution partner in the fast-growing GLP-1 market.
The move responds to a rapidly evolving U.S. weight-loss landscape since 2023, where branded GLP-1 drugs have become more available and affordable, and Hims & Hers plans to educate customers and transition appropriate patients to these approved treatments while maintaining robust support services. By synchronizing its domestic and international approaches and expanding access to leading GLP-1 brands, the company aims to consolidate its role as a major global platform for affordable, approved weight-loss medications and to leverage growth opportunities in the obesity-care segment.
The most recent analyst rating on (HIMS) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Hims & Hers Health stock, see the HIMS Stock Forecast page.
Spark’s Take on HIMS Stock
According to Spark, TipRanks’ AI Analyst, HIMS is a Neutral.
The score is driven primarily by improving fundamentals and upbeat guidance, but is held back by the 2025 leverage increase and weaker recent cash conversion/margins. Bearish technicals and a high P/E further temper the outlook, while earnings-call momentum and growth investments provide partial support.
To see Spark’s full report on HIMS stock, click here.
More about Hims & Hers Health
Hims & Hers Health, Inc. is a consumer-focused health and wellness platform that offers personalized medical care, including telehealth services and treatment programs, aimed at making it easier for people to address everyday health and wellness needs. The company provides tailored access to medications and clinical support across a range of conditions, emphasizing accessible, results-driven care for both body and mind.
Average Trading Volume: 28,172,766
Technical Sentiment Signal: Sell
Current Market Cap: $5.35B
Learn more about HIMS stock on TipRanks’ Stock Analysis page.